(PubMed) Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L
The potency of this combination therapy may provide a multi-faceted approach to treating various forms of sexual dysfunction by targeting both physiological and neurological aspects of sexual function simultaneously
Marketing teams must align with this broader clinical picture by emphasizing: Long-term metabolic and cardiovascular outcomes Improved patient adherence through oral administration Holistic care models integrating lifestyle, pharmacology, and education Positioning oral GLP1s in this expanded therapeutic context creates differentiation and deeper provider trust
While semaglutide aids weight loss, the initial adjustment period may provoke discomfort
Smaller Biotechs and Collaborators: Companies like Zealand Pharma, Glycadia, and others have GLP-1 analogs or co-agonists in early trials, often in partnership with larger pharma (e.g., Novo Nordisk collaboration with Zealand)
Volume 15 (Issue 2), Page 214